It was concluded that the subgroup of patients with poor liver function (albumin-bilirubin grade 2 or 3), high alpha-fetoprotein (≥ 200 ng/mL), and intermediate to advanced HCC (BCLC stage B or C) who received MDT care had specific improvements in survival benefits (47). Here, ALB is linked to hepatocellular carcinoma.